Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29751233 | 0.92 | IRAK4 (0.60) | IRAK4FLT3 | |
| SCHEMBL24608149 | 0.92 | IRAK4 (0.60) | IRAK4FLT3 | |
| SCHEMBL22848895 | 0.91 | IRAK4 (0.59) | IRAK4 | |
| SCHEMBL24608148 | 0.91 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL29751544 | 0.91 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL26346848 | 0.91 | IRAK4 (0.64) | IRAK4FLT3 | |
| SCHEMBL26355086 | 0.88 | IRAK4 (0.65) | IRAK4 | |
| SCHEMBL23890117 | 0.85 | IRAK4 (0.83) | IRAK4FLT3 | |
| SCHEMBL25599903 | 0.85 | IRAK4 (0.83) | IRAK4FLT3 | |
| SCHEMBL22848765 | 0.85 | IRAK4 (0.56) | IRAK4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885FLT3 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.